Search

1015 Result(s)
Sort by

EMPERIAL-heart-failure-toplineresults

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Watercress Soup Video

Watercress Soup Video

This delicate soup is easy to eat with plenty of fragrant flavour. Click here to find out how to make it.
Honey and Cinnamon Cookies video

Honey and Cinnamon Cookies video

Find out how to make these simple and sweet honey and cinnamon cookies from Taking Cancer On Through Flavour
Carrot Cake Video

Carrot Cake Video

Find out how to make this moist and delicious carrot cake from Taking Cancer on Through Flavour at home
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Why cancer care is personal for us

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Niha Agarwalla

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Do we keep our promise?

Do we keep our promise?

Find out from a father-daughter duo how we live up to our new People Promise.
What are acute exacerbations in IPF?

What are acute exacerbations in IPF?

Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.